Anuh Pharma Intrinsic Value
ANUHPHR Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹154.00 | ₹123.20 - ₹184.80 | +93.8% | EPS: ₹7.00, Sector P/E: 22x |
| Book Value Method | asset | ₹198.68 | ₹178.81 - ₹218.55 | +150.0% | Book Value/Share: ₹130.40, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹158.94 | ₹143.05 - ₹174.83 | +100.0% | Revenue/Share: ₹294.80, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹158.94 | ₹143.05 - ₹174.83 | +100.0% | EBITDA: ₹62.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹157.08 | ₹125.66 - ₹188.50 | +97.7% | CF Growth: 8.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹23.84 | ₹21.46 - ₹26.22 | -70.0% | EPS Growth: 3.5%, Fair P/E: 2.8x |
| Growth Adjusted P/E | growth | ₹110.58 | ₹99.52 - ₹121.64 | +39.1% | Revenue Growth: 10.6%, Adj P/E: 15.8x |
| ROE Based Valuation | profitability | ₹158.94 | ₹143.05 - ₹174.83 | +100.0% | ROE: 12.0%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹143.31 | ₹128.98 - ₹157.64 | +80.3% | EPS: ₹7.00, BVPS: ₹130.40 |
| Dividend Yield Method | dividend | ₹60.00 | ₹54.00 - ₹66.00 | -24.5% | DPS: ₹1.50, Target Yield: 2.5% |
Want to compare with current market value? Check ANUHPHR share price latest .
Valuation Comparison Chart
ANUHPHR Intrinsic Value Analysis
What is the intrinsic value of ANUHPHR?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Anuh Pharma (ANUHPHR) is ₹157.08 (median value). With the current market price of ₹79.47, this represents a +97.7% variance from our estimated fair value.
The valuation range spans from ₹23.84 to ₹198.68, indicating ₹23.84 - ₹198.68.
Is ANUHPHR undervalued or overvalued?
Based on our multi-method analysis, Anuh Pharma (ANUHPHR) appears to be trading below calculated value by approximately 97.7%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 188.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.56 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 12.0% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 8.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.45x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Anuh Pharma
Additional stock information and data for ANUHPHR
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹37 Cr | ₹27 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹13 Cr | ₹13 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹54 Cr | ₹32 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹29 Cr | ₹25 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹-19 Cr | ₹-19 Cr | Negative Cash Flow | 3/10 |